Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998824 | 1.00 | ITGA4 (0.51) | ITGA4ITGB7ITGB3ITGA2BCTSK | |
| SCHEMBL19410123 | 0.81 | SLC16A3 (0.48) | ITGA4ITGB7ITGB3ITGA2BCTSK | |
| SCHEMBL30711155 | 0.81 | SLC16A3 (0.48) | ITGA4ITGB7ITGB3ITGA2BCTSK | |
| SCHEMBL19410121 | 0.81 | SLC16A3 (0.48) | ITGA4ITGB7ITGB3ITGA2BCTSK | |
| SCHEMBL8486002 | 0.79 | ADAM17 (0.49) | ITGA4ITGB7ITGB3ITGA2BCTSK | |
| SCHEMBL9082551 | 0.79 | ADAM17 (0.49) | ITGA4ITGB7ITGB3ITGA2BCTSK | |
| SCHEMBL479010 | 0.77 | TACR1 (0.68) | ITGB3ITGA2BCTSKCTSLCTSB | |
| SCHEMBL220648 | 0.77 | TACR1 (0.68) | ITGB3ITGA2BCTSKCTSLCTSB | |
| SCHEMBL7372270 | 0.77 | TACR1 (0.68) | ITGB3ITGA2BCTSKCTSLCTSB | |
| SCHEMBL219151 | 0.77 | TACR1 (0.68) | ITGB3ITGA2BCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | ITGA4 4230/4885ITGB7 3438/4885ITGB3 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.